RU2678767C2 - Ингибиторы протеинкиназ - Google Patents

Ингибиторы протеинкиназ Download PDF

Info

Publication number
RU2678767C2
RU2678767C2 RU2014145285A RU2014145285A RU2678767C2 RU 2678767 C2 RU2678767 C2 RU 2678767C2 RU 2014145285 A RU2014145285 A RU 2014145285A RU 2014145285 A RU2014145285 A RU 2014145285A RU 2678767 C2 RU2678767 C2 RU 2678767C2
Authority
RU
Russia
Prior art keywords
mmol
compound
added
solution
room temperature
Prior art date
Application number
RU2014145285A
Other languages
English (en)
Russian (ru)
Other versions
RU2014145285A (ru
Inventor
Ален ЛОРЕН
Янник Роуз
Джеймс Б. ДЖЕКУИТ
Original Assignee
ГБ005, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA2779184A external-priority patent/CA2779184A1/en
Priority claimed from CA2813299A external-priority patent/CA2813299A1/en
Application filed by ГБ005, Инк. filed Critical ГБ005, Инк.
Publication of RU2014145285A publication Critical patent/RU2014145285A/ru
Application granted granted Critical
Publication of RU2678767C2 publication Critical patent/RU2678767C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
RU2014145285A 2012-05-31 2013-05-28 Ингибиторы протеинкиназ RU2678767C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CA2,779,184 2012-05-31
CA2779184A CA2779184A1 (en) 2012-05-31 2012-05-31 Protein kinase inhibitors
CA2813299A CA2813299A1 (en) 2013-04-17 2013-04-17 Protein kinase inhibitors
CA2,813,299 2013-04-17
PCT/CA2013/000513 WO2013177668A1 (en) 2012-05-31 2013-05-28 Protein kinase inhibitors

Publications (2)

Publication Number Publication Date
RU2014145285A RU2014145285A (ru) 2016-07-20
RU2678767C2 true RU2678767C2 (ru) 2019-02-01

Family

ID=49672221

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014145285A RU2678767C2 (ru) 2012-05-31 2013-05-28 Ингибиторы протеинкиназ

Country Status (11)

Country Link
US (1) US9796716B2 (enExample)
EP (1) EP2855484A4 (enExample)
JP (1) JP6175495B2 (enExample)
KR (2) KR101972990B1 (enExample)
CN (1) CN104379586B (enExample)
BR (1) BR112014029718A2 (enExample)
CA (1) CA2874211A1 (enExample)
HK (1) HK1208460A1 (enExample)
IN (1) IN2014MN02338A (enExample)
RU (1) RU2678767C2 (enExample)
WO (1) WO2013177668A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2833867A1 (en) * 2013-11-21 2015-05-21 Pharmascience Inc. Protein kinase inhibitors
CA2834528A1 (en) * 2013-11-26 2015-05-26 Pharmascience Inc. Protein kinase inhibitors
MX2017000331A (es) * 2014-07-07 2017-08-25 Eternity Bioscience Inc Compuestos de aminopiridazinona como inhibidores de quinasas de proteina.
GB201508747D0 (en) * 2015-05-21 2015-07-01 Univ Edinburgh Compounds
CA3025813A1 (en) * 2015-05-27 2016-12-01 Gb005, Inc. Inhibitors of the tec kinase enzyme family
US10927087B2 (en) 2015-12-07 2021-02-23 Dic Corporation Method for producing polymerizable compound
WO2017134685A2 (en) * 2016-02-02 2017-08-10 Sun Pharma Advanced Research Company Limited Novel hydrazino compounds as btk inhibitors
CN109369654A (zh) * 2018-11-20 2019-02-22 山东大学 1，3-二取代-4-氨基吡唑并嘧啶类化合物及其制备方法和应用
CN111454268B (zh) * 2019-01-18 2023-09-08 明慧医药（上海）有限公司 作为布鲁顿酪氨酸激酶抑制剂的环状分子
US20250042904A1 (en) * 2021-11-15 2025-02-06 Wigen Biomedicine Technology (shanghai) Co., Ltd. Compounds used as src inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080926A1 (en) * 2001-03-22 2002-10-17 Abbott Gmbh & Co. Kg Pyrazolopyrimidines as therapeutic agents
EA200901313A1 (ru) * 2007-03-28 2010-04-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
WO2011046954A1 (en) * 2009-10-13 2011-04-21 Ligand Pharmaceuticals Inc. Hematopoietic growth factor mimetic small molecule compounds and their uses

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1212327T3 (da) * 1999-09-17 2003-12-15 Abbott Gmbh & Co Kg Pyrazolopyrimidiner som terapeutiske midler
WO2001019828A2 (en) 1999-09-17 2001-03-22 Basf Aktiengesellschaft Kinase inhibitors as therapeutic agents
AU763356C (en) * 1999-12-27 2004-08-26 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
AUPR392301A0 (en) 2001-03-23 2001-04-26 University Of Newcastle Research Associates Limited, The Protein phosphatase inhibitors
CA2450777C (en) * 2001-08-10 2013-04-09 Novartis Ag Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
CA2663116C (en) 2006-09-22 2014-06-10 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
CN105408334B (zh) * 2013-05-21 2017-10-10 江苏迈度药物研发有限公司 作为激酶抑制剂的取代的吡唑并嘧啶类化合物
CN103787839B (zh) 2014-01-21 2015-12-02 苏州昊帆生物科技有限公司 合成2,3,4,5,6-五氟苯酚的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080926A1 (en) * 2001-03-22 2002-10-17 Abbott Gmbh & Co. Kg Pyrazolopyrimidines as therapeutic agents
EA200901313A1 (ru) * 2007-03-28 2010-04-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
WO2011046954A1 (en) * 2009-10-13 2011-04-21 Ligand Pharmaceuticals Inc. Hematopoietic growth factor mimetic small molecule compounds and their uses

Also Published As

Publication number Publication date
IN2014MN02338A (enExample) 2015-08-14
EP2855484A1 (en) 2015-04-08
BR112014029718A2 (pt) 2017-06-27
CN104379586B (zh) 2018-01-16
RU2014145285A (ru) 2016-07-20
US20150191473A1 (en) 2015-07-09
KR20150015527A (ko) 2015-02-10
KR101972990B1 (ko) 2019-04-26
EP2855484A4 (en) 2015-12-16
US9796716B2 (en) 2017-10-24
CN104379586A (zh) 2015-02-25
CA2874211A1 (en) 2013-12-05
WO2013177668A1 (en) 2013-12-05
HK1208460A1 (en) 2016-03-04
JP2015518009A (ja) 2015-06-25
JP6175495B2 (ja) 2017-08-02
KR20190043648A (ko) 2019-04-26

Similar Documents

Publication Publication Date Title
RU2678767C2 (ru) Ингибиторы протеинкиназ
JP6001053B2 (ja) タンパク質キナーゼ阻害剤
RU2679122C2 (ru) Ингибиторы протеинкиназ
CA2667487C (en) Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
EP2694515B1 (en) Protein kinase inhibitors
JP2016510042A (ja) ピリドピリミジンまたはピリミドピリミジン系化合物、その製造方法、薬剤組成物及びその用途
CA2833701A1 (en) Protein kinase inhibitors
CA2779184A1 (en) Protein kinase inhibitors
CA2813299A1 (en) Protein kinase inhibitors
CA2833867A1 (en) Protein kinase inhibitors
WO2014029007A1 (en) Protein kinase inhibitors

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200529